Hutch News

Hutch News

Stories tagged 'VIDD Research Interests'

Antimicrobial stewardship preserves a ‘shared resource’

Gains in cancer survival at risk due to surge in multi-drug resistant superbugs

May 4, 2017 | By Mary Engel / Fred Hutch News Service

Antibiotics and other antimicrobials are unique among medications, a “shared resource” that we need to preserve, much as we steward our environment and natural resources, says Fred Hutch clinician-infectious disease researcher Dr. Catherine Liu. Overuse or misuse can lead to drug-resistant bugs that can then spread to new hosts and in some cases even spread their resistance genes to different microorganisms, posing a risk to society at large.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

March 23, 2017

HIV researcher Julie Overbaugh leads Hutch graduate education; Dr. Janghee Woo named second CTI BioPharma International Postdoctoral Research Fellow

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Jan. 5, 2017

Dr. Jonathan Bricker offers 5 steps for keeping resolutions in the new year; Dr. Trevor Bedford a finalist for first-ever Open Science Prize; 425 Magazine salutes HIV researcher Dr. Larry Corey and community advocate Michael Louella

View story >


On the path to a new-generation malaria vaccine

New approach using genetically modified parasite ‘primes the immune system’ in first human trial

Jan. 4, 2017 | By Mary Engel / Fred Hutch News Service

Volunteers in a clinical trial led by Fred Hutch's Dr. Jim Kublin endured 150 to 200 mosquito bites in one 10-minute session to test a new approach to a malaria vaccine that uses genetically attenuated, or weakened, parasites to stimulate an immune response to malaria without causing disease.

View story >


Experimental herpes drug more effective than standard treatment

Pritelivir reduces viral shedding and lesions better than valacyclovir, study shows

Dec. 20, 2016 | By Mary Engel / Fred Hutch News Service

The results of the phase 2, randomized, double-blind trial published today in JAMA showed that when people with genital herpes took a daily oral dose of pritelivir, they reduced their rate of viral shedding by half compared to when they took valacyclovir. They also had fewer genital sores and less pain.

View story >


Renewed hope for halting HIV through vaccine

At International AIDS Conference, researchers are optimistic as two new HIV vaccine trials are set to explore different approaches for protection

July 19, 2016 | By Mary Engel / Fred Hutch News Service

At the International AIDS Conference in Durban, South Africa, researchers are optimistic as two new HIV vaccine trials are set to explore different approaches for protection.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.